OR WAIT 15 SECS
In a phase IIa study of patients with neovascular age-related macular degeneration, a single subretinal injection of rAAV.sFlt-1 gene therapy demonstrated acceptable safety, but not a complete or durable anti-VEGF response. Additional preclinical research is under way.
Take-home message: In a phase IIa study of patients with neovascular age-related macular degeneration, a single subretinal injection of rAAV.sFlt-1 gene therapy demonstrated acceptable safety, but not a complete or durable anti-VEGF response. Additional preclinical research is under way.
Reviewed by Jeffrey S. Heier, MD
Boston-In a phase IIa study, rAAV.sFlt-1 gene therapy (AVA-101, Avalanche Biotechnologies) for neovascular age-related macular degeneration (AMD) demonstrated acceptable safety.
However, the therapy failed to provide a complete or durable anti-vascular endothelial growth factor (VEGF) response.
The results are disappointing, but the outcomes of the trial do not necessarily spell the end of the investigational product’s development, according to Jeffrey S. Heier, MD.
“I still believe gene therapy is well-suited for the management of retinal disease-it has a proven track record in humans, and for a variety of reasons, the retina is ideally suited for developing gene-based therapies,” said Dr. Heier, director, vitreoretinal service, Ophthalmic Consultants of Boston. “Furthermore, there is a strong rationale for developing a sustained delivery product that could help with the ongoing treatment burden.
“Now, numerous factors are being studied in an effort to fully understand the responses observed in the phase IIa study of AVA-101, and more preclinical research is under way that will hopefully provide insight into variables that can improve outcomes,” he said.
AVA-101 uses an adeno-associated viral vector to deliver a gene that produces naturally occurring sFlt-1 (soluble VEGF receptor-1).
The phase IIa study enrolled patients with treatment-naïve or previously treated neovascular AMD. A total of 32 patients were randomly assigned 2:1 to receive a single subretinal injection of AVA-101 or control.
All patients received an intravitreal injection of ranibizumab 0.5 mg (Lucentis, Genentech) at day 0 and month 1. The gene therapy group underwent core vitrectomy and received the AVA-101 subretinal injection adjacent to the macula on day 7, and all patients returned for monthly follow-up visits through week 52.
During the course of the study, all patients were eligible for rescue treatment with ranibizumab, which was given as needed based on pre-specified retreatment criteria.
At week 52, mean visual acuity increased from baseline by 2.2 letters in the AVA-101 group while the control arm showed a mean loss of 9.3 letters.
“There was a statistically significant difference between the treatment and control arm, but this was largely driven by poor performance in the control arm due to 3 subjects losing at least 4 lines of visual acuity from baseline,” Dr. Heier said.
However, anatomic outcomes were better in the control arm. Center point thickness (CPT) at 1 year showed a 27-µm increase from baseline in the AVA-101 arm while CPT was 85 µm less than baseline in the control arm.
There were no serious ocular adverse events associated with the investigational therapy and no systemic safety signals attributed to AVA-101. All patients in the AVA-101 arm who were phakic at baseline developed a cataract, and three AVA-101 patients developed a moderate vitreous hemorrhage (14%) that was related to the sclerotomy or trocar insertion used for delivery.
When results do not turn out as expected, Dr. Heier said it becomes necessary to go back to basics and try to understand the underlying reasons. He pointed out that in the study, there was significant variation in the number of rescue ranibizumab injections received by patients in the treatment arm.
“For example, there may be something we can learn from determining why some patients received very few ranibizumab injections and others received many more,” he said.
Other issues being evaluated include whether the subretinal delivery route and the AAV vector itself are optimal-not all vectors are created equal, Dr. Heier said.
He also noted that the experience of the phase IIa study underscores the challenges in conducting surgical treatment trials.
“Surgical trials for treating medical diseases are extremely difficult to design,” Dr. Heier said.
Issues to consider pertain to patient selection criteria, what represents an appropriate sham control, and masking of patients and examiners.
Dr. Heier also made the point that the control arm of a surgical trial providing extended delivery treatment for neovascular AMD is difficult to implement.
Although standard of care treatment today mandates anti-VEGF therapy for any level of fluid because it represents early disease recurrence, subtle fluid may not be an indicator of disease recurrence in an eye treated with an extended delivery treatment.
“Perhaps the latter patients are at less risk of vision loss when subtle fluid is seen,” Dr. Heier said.
In addition, a surgical approach introduces confounders that can be difficult to control for within a clinical trial.
“It is much more difficult to control for differences in eyes in a surgical study than in a study of an intravitreal injection,” Dr. Heier said. “There are also differences in surgeon skills and other issues to consider, such as where to place the bleb and how to manage cataracts.”
Jeffrey S. Heier, MD
This article was adapted from Dr. Heier’s presentation during Retina Subspecialty Day at the 2015 meeting of the American Academy of Ophthalmology. Dr. Heier is a scientific advisor to Avalanche Biotechnologies.